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What is already known on this topic?
Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in neonates and infants. Sirolimus may be
an effective treatment option in patients with CHI resistant to traditional medical therapy or failure of subtotal pancreatectomy, but
experience is limited.

What this study adds?
This article further revealed the safety and efficacy of sirolimus in the very young patient with CHI, which can make us better understand
the new treatment. The patient has a heterozygous ABCC8 mutation. It’s also the first Chinese CHI patient with heterozygous ABCC8
mutation who used sirolimus.

Abstract
Congenital hyperinsulinism (CHI) is the most common cause of severe, persistent hypoglycemia in neonates and infants. If the patient
does not respond to medical treatment the currently available treatment is subtotal pancreatectomy, but some patients still experience
severe hypoglycemia after surgery. Sirolimus, a mammalian target of rapamycin inhibitor has recently been reported to be effective
in the treatment of insulinoma and CHI patients. Here we report a patient with CHI who had prolonged hypoglycemia after subtotal
pancreatectomy. The patient had a heterozygous mutation in ABCC8 but was unresponsive to an optimal dose of diazoxide (15 mg/
kg/day) and octreotide (30 µg/kg/day). The patient subsequently had subtotal pancreatectomy but severe and persistent hypoglycemia
continued post-operatively. Sirolimus was commenced. There was a remarkable improvement in glycemic control without major adverse
events, although he required a small dose of octreotide to maintain euglycemia. Sirolimus therapy was discontinued when the patient
was 15 months old. At the time of this report, at an age of three years and eight months, the patient continues to maintain good glycemic
control. This report suggests that sirolimus may be an effective treatment option in patients with CHI resistant to established medical
therapy or failure of subtotal pancreatectomy. However, the long-term safety requires study in larger groups of very young patients.
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Introduction
Congenital hyperinsulinism (CHI), the major cause of
persistent hypoglycemia in neonates and infants, is
characterized by inappropriate insulin secretion from
pancreatic beta cells in the presence of low blood glucose
levels (1). Prompt and early management of these patients

is very important for neurological prognosis (1,2). The
incidence of CHI in the general population is estimated at
1/30,000-1/50,000 live births (3,4). Two major histologic
subtypes have been described: diffuse (60-70% of patients)
and focal (30-40% of patients) (5). Mutations in ABCC8 and
KCNJ11 cause severe CHI that is unresponsive to medical
treatment with diazoxide and octreotide (1). The current
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treatment for patients is a subtotal pancreatectomy (5,6).
However, despite surgery, 40-59% of operated patients
continue to experience severe and persistent hypoglycemia
for months, or even years (7), and nearly 100% will develop
diabetes mellitus within 11 years of surgery (8). Therefore,
medical therapeutic alternatives should be considered with
the aim of reducing insulin secretion and thereby preventing
neurologic consequences. Constitutive activation of the
mammalian target of rapamycin (mTOR) pathway has been
postulated as a mechanism for hyperinsulinism and β-cell
hyperplasia in diffuse CHI (9). Recent advances have shown
the effectiveness of sirolimus, an mTOR inhibitor, in infants
with severe diffuse CHI that had been unresponsive to
medical therapy (10,11,12,13), one of whom had undergone
subtotal pancreatectomy (10). During follow-up, no major
adverse events was observed in the patients. We report a
patient with CHI who failed to become euglycemic after
pancreatectomy. The patient was successfully treated with
sirolimus without further surgical intervention.
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mg/kg/min, administered parenterally via a central venous
catheter. Diazoxide therapy was commenced on PD 14 and
was gradually increased to an optimal dose of 15 mg/kg/
day but with no response. On PD 20 Nifedipine was added
to the therapeutic regimen, but it was discontinued after a
week due to lack of response. Subcutaneous octreotide was
initiated on PD 29. The octreotide dose was increased to a
maximum dose (30 μg/kg/day), but resulted in only a 20%
reduction in total glucose requirement. On PD 55, a subtotal
pancreatectomy was performed at the Children’s Hospital of
Fudan University, Shanghai, China. Histopathological results
confirmed diffuse hyperplasia of the islet cells (Figure 2).
Subcutaneous octreotide was discontinued after the surgery,

Case Report
The patient, a male infant, was born by cesarean at the 39th
week of gestation to nonconsanguineous Chinese parents
after an uneventful pregnancy. Birth weight was 3600 g.
On the first day of his life, he was found to have severe
hypoglycemia when he developed lethargy and seizures.
He required high intravenous glucose infusion rate (GIR)
(13 mg/kg/minute) to maintain normal blood glucose
level. As he had persistent and severe hypoglycemia, he
was transferred to our hospital for further management
on postnatal day (PD) 13. The following results were
obtained during an episode of hypoglycemia: glucose, 2.3
mmol/L; concomitant serum insulin, 13.52 (normal: 4.0323.46) µIU/mL; C-peptide 4.25 (normal: 0.3-3.73) ng/
mL; beta-hydroxybutyrate < 0.1 mmol/L. He had normal
thyroid-stimulating hormone and free T4 levels. Metabolic
screening profiles in plasma and urine were non-specific.
Genetic analysis subsequently confirmed a novel mutation,
c.1585_1587del, in exon 10 of the ABCC8 gene (Figure 1),
which resulted in the deletion of glutamic acid at position
529 (p.del529E) of ABCC8 protein and produced ABCC8
protein with a shorter topological domain (www.ncbi.nih.
gov/orffinder and www.uniprot.org). The mutations in the
topological domain affected the function of the ABCC8 gene
(14). According to American College of Medical Genetics
criteria, the mutation is of uncertain significance and should
be further studied (15). His father has the same mutation,
but the phenotype is normal. Magnetic resonance imaging
of the patient’s brain showed bilateral abnormalities of the
parietal white matter. Subsequently, maximal GIR was 16
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Figure 1. Sanger sequencing of ABCC8 gene in the proband
and his parents: the arrows showed the mutation site of the
ABCC8 gene

Figure 2. Histopathological result confirmed diffuse
hyperplasia of the islet cells. The arrows showed
hypersecretion of islet cells in islets
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but the minimum GIR remained 10 mg/kg/min. Octreotide
subcutaneous injection was resumed with the dose of 30
μg/kg/day. Over the next few weeks, there was no reduction
in his glucose requirement. The total volume of nasogastric
and parenteral fluids reached 190 mL/kg/d and it was also
very difficult to establish a central venous line.
In view of the multiple medical problems, further surgery
was being contemplated. After reviewing the risks and
beneﬁts, Sirolimus was considered as an alternative
treatment option. Sirolimus treatment was begun at 4.5
months of age at a dose of 0.5 mg/m2/day. The dose was
gradually increased, with the goal of reaching a serum trough
level of 5-15 ng/dL. The serum trough level of sirolimus was
measured every 5-7 days. After 10 days of treatment with
sirolimus, intravenous glucose infusion and subcutaneous
octreotide were gradually tapered. Four weeks following
initiation of sirolimus, stable blood glucose homeostasis
was achieved without intravenous glucose infusion, and the
octreotide dose was reduced from 30 μg/kg/day to 15 μg/kg/
day. The patient was able to tolerate fasting for four hours
while maintaining a blood glucose level >60 mg/dL prior
to discharge as recorded by continuous glucose monitoring.
The patient was followed regularly for assessment of
glycemic control and measurement of serum sirolimus
levels. Sirolimus was discontinued at 15 months of age. The
maximum dose of sirolimus used was 3.2 mg/m2/day.
The patient had good glycemic control after cessation of
sirolimus. However, at times of poor appetite, there was
still a requirement for low dose octreotide (2 μg/kg/day) to
control blood glucose. Complete blood count, serum lipid
profile, and renal and liver function have been monitored
regularly and no significant side effects were observed,
except for mildly elevated triglycerides at two years and
three months old. At the time of writing the patient was
three years and six months old. At the last visit, the patient
was able to tolerate fasting for six hours according to
continuous glucose monitoring. The blood glucose was 95
mg/dL and the insulin was 4.9 µIU/mL at the end of the six
hours fasting.

Discussion
The management of diffuse CHI that is unresponsive to
diazoxide poses a major therapeutic challenge. While subtotal
pancreatectomy remains the procedure of choice following
failure of medical therapy, the surgery is not completely
curative and may still be associated with unsatisfactory
glycemic
control.
Fluorine-18-dihydrophenylalanine
positron emission tomography was not performed in our
patient before surgery, since it was not available in children

Chen Q et al.
Sirolimus Therapy in Congenital Hyperinsulinism

in China at the time, but based on the increased number
of islets and enlarged volume of partial regional islets
reported histopathologically, as well as the recurrent severe
hypoglycemia after subtotal pancreatectomy, the patient
likely had a diffuse CHI. The patient has a heterozygous
mutation in ABCC8. Definitely, most dominant acting
monoallelic potassium channel ATP gene mutations cause
mild diazoxide responsive CHI. However, Saint-Martin et
al (16) reported that some dominant ABCC8 mutations are
responsible for a subset of diffuse, diazoxide-unresponsive
forms of CHI. The mechanism in these cases is unclear and
needs further study. After pancreatectomy, the total amount
of nasogastric and parenteral fluids had reached maximum,
and it was also very difficult to establish a central venous line.
Therefore, there was a need for an alternative treatment,
minimizing the requirement for repeat pancreatectomy,
and the burden of demanding medical and nutritional
intervention in our patient.
Sirolimus has been reported as a treatment option for
unresponsive CHI (10,11,12,13). No major adverse reactions
were observed during follow-up period in these case reports,
though a recent study in two large centers showed that
mTOR inhibition achieved euglycemia, fasting tolerance
and reduced medical therapy in only 30% of patients
and more adverse events were observed (17). mTOR is a
serine and threonine protein kinase that integrates signals
from mitogens and nutrients, glucose and amino acids,
to regulate cellular growth and proliferation (18). The
mechanism of mTOR inhibitors in CHI has not been fully
delineated. Hyperplasia of β-cells has been proposed to be
involved in the trans-differentiation of mature acinar and
ductal elements of exocrine pancreas into insulin-secreting
cells, which is possibly mediated by the constitutive
activation of the mTOR pathway (19). mTOR inhibition
may also affect the number of insulin receptors that are
present in pancreatic β-cells, which would reduce insulin
production (20). Sirolimus has been used in vitro to induce
fulminant diabetes by promoting insulin resistance and
reducing β-cell mass through apoptosis induction (21,22).
Furthermore, long-term management with sirolimus was
found to cause glucose intolerance by up-regulating hepatic
gluconeogenesis (23). It is postulated that the mechanism of
mTOR inhibition is also reduced during islet cell proliferation
(11,12). This was recently confirmed by genomic datasets
implicating the insulin-like growth factor 1/mTOR/Akt
pathway in the pathophysiology of CHI (9). Another study
has shown that mTOR pathways are not downregulated
in keeping with non-responsiveness to sirolimus and the
observation that proliferation remains high after treatment
with sirolimus (17).
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The reported adverse effects of sirolimus treatment include
stomatitis, fatigue, immunosuppression, increased risk of
infections, renal function abnormalities, hyperlipidemia,
and pneumonitis (22,24), which are reversible with dose
reduction. Mild elevation of triglycerides was observed
in our patient. Sirolimus appears to be well tolerated in
children post renal transplant, even when initiated at higher
doses (6 mg/m2/day) and thereafter adjusted to achieve
target trough levels in the range of 10-20 ng/mL (25). These
studies suggest a reasonable safety profile for sirolimus, but
the long-term safety remains unknown in younger children,
particularly in neonates.

3. Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A,
Valayannopoulos V, Brunelle F, Fournet JC, Robert JJ, Aigrain Y,
Bellanné-Chantelot C, de Lonlay P. Congenital hyperinsulinism: current
trends in diagnosis and therapy. Orphanet J Rare Dis 2011;6:63.

Conclusion

8. Arya VB, Senniappan S, Demirbilek H, Alam S, Flanagan SE, Ellard
S, Hussain K. Pancreatic endocrine and exocrine function in
children following near-total pancreatectomy for diffuse congenital
hyperinsulinism. PLos One 2014;9:e98054.

In conclusion, sirolimus was a well-tolerated treatment in
our patient with CHI who otherwise would have required
second surgery, and no major adverse events were observed
during the period of 10 months of treatment. Sirolimus
may be a feasible option for selected CHI patients with no
contraindication, either before surgery or as an adjunctive
therapy, although the mechanism and long-term adverse
effects of such treatment require further study.
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